MIMEDX EPIFIX® Receives Reimbursement Approval in Japan
Provides Favorable Access to a New $500 Million Market for the Treatment of Refractory Diabetic and Venous Ulcers for EPIFIX – the First and Only Amniotic...
Source: globenewswire.com
Refractory Diabetic News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Refractory Diabetic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.